undamentalytics Newsletter
Sign in

Mettler Toledo (MTD) stock

Add to watchlist

Add holding +

NYSE: MTD NYSE Life Sciences Tools & Services Next results ~November 5, 2026

B Fundamentals grade

Mettler Toledo is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$740

Cash-flow model

Base case. Range ~$530–$1000 across our lower- and higher-growth cases (-0.8%–9.2% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 56% below it.

Price used: $1678.19, November 2, 2026

Mettler Toledo valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Mettler Toledo files

Where Mettler Toledo stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $4.13bn, up 6.9% on a year earlier, about the same pace as a quarter earlier. Free-cash-flow margin fell to 20.9% from 21.9% a year earlier. The diluted share count is down 3.0% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 2 of our 6 financial-health checks. Our cash-flow model value is $738 a share, against a share price of $1,629. At that price, our model says the market is pricing in about 17.2% a year of cash-flow growth for five years, faster than the 2.1% a year revenue growth it has delivered.

Source: 10-Q filed July 31, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Mettler Toledo's trailing-twelve-month revenue grew 6.9% year on year, with a free-cash-flow margin of 20.9%. Where it stands out: net margin of 21.9% ranks 1 of 54 life sciences tools & services companies we cover. Where it lags: long-term debt as % of assets of 55.7% ranks 33 of 35 life sciences tools & services companies we cover.

Our discounted-cash-flow model values the business at ~$740 per share in the base case (~$530–$1000 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Share count shrinking (buybacks): Diluted shares outstanding fell 3.0% year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Strong cash generation. 20.9% of revenue turned into free cash flow, against a median of -1.3% for life sciences tools & services companies we cover.
  • Shrinking share count. Diluted shares fell 3.0% in a year, so each share owns more of the business.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Priced above our value. The share price of $1,678.19 is 56% above our value per share of $740.
  • Insiders selling. 6 insiders sold $36M of stock over the past 365 days and none bought (0% under pre-set trading plans).
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 55.7% ranks 33 of 35 life sciences tools & services companies we cover (median 26.3%).

Latest results: FY2026 Q2

Filed July 31, 2026
Earnings per share
$11.46 against an average estimate of $10.80: beat by 6.1%
Revenue
$1.03bn, up 4.5% on a year earlier
Share reaction
+2.0% in the first session after the results on July 30, 2026, against +2.4% for the S&P 500
Guidance given
local currency sales growth 4% (third quarter of 2026); adjusted EPS $12 to $12.15 (third quarter of 2026)
Next report
November 5, 2026; average EPS estimate $12.09

Mettler Toledo's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.2%
  • 1 week+0.5%
  • 1 month+12.9%
  • This year+20.4%
  • 1 year+18.5%
  • 5 years+14.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$4.1B
Net margin
21.9%
EPS (TTM, diluted)
$44.44

Growth

Revenue growth
+6.9%
Change in growth rate
+0.1 pts
Share count change
−3.0%

Cash

Free cash flow (TTM)
$864M
FCF margin
20.9%
Stock pay % of revenue
0.6%

Earnings

Last results
July 30, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Insider trade
  3. Leadership
  4. Insider trade
  5. Results
  6. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Mettler Toledo valuation models and calculator

What the price is pricing in

The share price implies about 18.1% a year of cash-flow growth for five years.That is faster than the 2.1% a year revenue growth Mettler Toledo has delivered.

  • Priced in18.1%
  • Last 12 months6.9%
  • 3 years a year1.5%
  • 5 years a year2.1%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($1701.63, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$740
Price used
$1701.63close November 3, 2026
Implied change
▼ 57%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Mettler Toledo's free cash flow after stock-based pay with after-tax interest added back ($957M, FY2026 Q2 TTM), growing 4.6% and 4.4% in the next two years (forecasts, guidance and its record), then back to 4.2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$530–~$1000 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Mettler Toledo's free cash flow after stock-based pay ( $957M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Mettler Toledo as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.99 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$740 ~$530–$1000 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1200 ~$930–$1500 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: return on equity above 40%: buybacks or intangibles make book value too small an anchor
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$590 ~$510–$700 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$810 ~$590–$1200 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Mettler Toledo with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −28%
  • Revenue growth 5 points higher ▲ +36%
  • Free-cash-flow margin 1 point lower ▼ −5%
  • Last year's free-cash-flow margin change, if it persists ▼ −5%
  • Discount rate 1 point higher ▼ −17%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $538$766$1068$1465$1983$2653
8.5% $389$554$771$1056$1425$1901
10% $298$426$593$811$1093$1453

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$339.13$418.56$619.52$565.58$793.28$1139.68$1697.21$1445.45$1212.96$1223.68$1394.19$1678.19
Market value$9.6bn$11.3bn$16.4bn$14.6bn$19.8bn$27.6bn$39.8bn$32.8bn$26.7bn$26.1bn$28.8bn$34.2bn
+ Net debt (− = net cash)$491m$735m$831m$857m$1.1bn$1.2bn$1.6bn$1.9bn$2.0bn$2.0bn$2.1bn$2.1bn
Enterprise value$10.1bn$12.0bn$17.2bn$15.4bn$20.9bn$28.8bn$41.4bn$34.8bn$28.7bn$28.0bn$30.9bn$36.3bn
Multiples
Price / sales 4.0x4.5x6.0x5.0x6.6x8.9x10.7x8.4x7.0x6.7x7.2x8.3x
Price / earnings 27.2x29.4x43.5x28.4x35.3x45.8x51.8x37.6x33.8x30.2x33.2x37.8x
Price / free cash flow 26.8x33.6x42.0x34.5x39.1x43.6x49.7x44.5x31.0x30.2x34.0x39.6x
EV / EBITDA ————————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

90 /100

Strong moat

How hard Mettler Toledo's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 34.5% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 58.5%, moving by 0.9 percentage points (standard deviation) across 10 years.

  • Durability 16 / 20

    Net margin has been a median 19.2%; its worst year was 13.5%.

  • Cash conversion 20 / 20

    Free cash flow was positive in 10 of 10 years, at a median 19.6% of revenue.

  • Discipline 20 / 20

    The diluted share count fell 14.6% over five years; stock-based pay has been a median 0.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (95 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $1.1bn and EPS of $12.09 (range $11.82 to $12.28) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $47.35 +11% $4.2bn +5%
Next $51.76 +9% $4.4bn +5%

Next year's EPS estimate has moved +1.0% in 90 days, across 13 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +1.5% on 90 days ago. In the last 30 days, 4 analysts raised Mettler Toledo's forecast and 1 cut it.

Consensus EPS forecast Mettler Toledo, last 90 days
$46.00 $48.00 $50.00 $52.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $46.66 Current fiscal year, 60 days ago: $47.34 Current fiscal year, 30 days ago: $47.34 Current fiscal year, 7 days ago: $47.35 Current fiscal year, Now: $47.35 $47.35 Next fiscal year, 90 days ago: $51.27 Next fiscal year, 60 days ago: $51.69 Next fiscal year, 30 days ago: $51.70 Next fiscal year, 7 days ago: $51.76 Next fiscal year, Now: $51.76 $51.76

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $46.66$51.27
60 days ago $47.34$51.69
30 days ago $47.34$51.70
7 days ago $47.35$51.76
Now $47.35$51.76

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $10.80 $11.46 +6.1%
Mar 2026 $8.71 $8.91 +2.3%
Dec 2025 $12.81 $13.36 +4.3%
Sept 2025 $10.66 $11.15 +4.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, July 30, 2026
  • local currency sales full year 2026 4% growth to 5% growth Non-GAAP
    “For the full year 2026, management anticipates local currency sales will increase approximately 4% to 5% excluding tariff refunds to customers.” source
  • local currency sales third quarter of 2026 about 4% growth
    “Based on today's assessment, management anticipates local currency sales for the third quarter of 2026 will increase approximately 4%.” source
  • Adjusted EPS full year 2026 $47.15 to $47.50 Non-GAAP
    “Adjusted EPS is forecast to be in the range of $47.15 to $47.50, representing growth of approximately 10% to 11%.” source
  • Adjusted EPS growth rate full year 2026 10% growth to 11% growth Non-GAAP
    “Adjusted EPS is forecast to be in the range of $47.15 to $47.50, representing growth of approximately 10% to 11%.” source
  • Adjusted EPS third quarter of 2026 $12.00 to $12.15 Non-GAAP
    “Adjusted EPS is forecast to be $12.00 to $12.15, a growth rate of 8% to 9%.” source
  • Adjusted EPS growth rate third quarter of 2026 8% growth to 9% growth Non-GAAP
    “Adjusted EPS is forecast to be $12.00 to $12.15, a growth rate of 8% to 9%.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Mettler Toledo's revenue by +4.6% next year and +4.4% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+5.0%, weight 55%) , management guidance (+4.0%, weight 19%) and the company's own record (+4.2%, weight 26%) . How the weights are set.

Analyst recommendations

13 analysts, Oct 2026
Buy538%
Hold646%
Sell215%

Monthly trend

  1. Oct 2026146213
  2. Sep 20261471114
  3. Aug 2026146112
  4. Jul 2026146112

Counts of recommendations published by analysts covering Mettler Toledo, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.8%
of tradable shares
Days to cover
2.85
at average volume
Short interest, 1 month
−6%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.4%
of shares
Employees
16,600
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +18.5%

$1416.29 on October 31, 2025 to $1678.19

ThenNowEffect
Revenue (last 12 months) $3.9bn $4.1bn +6.9%
Net margin 21.5% 21.9% +2.1%
P/E multiple 35.9x 37.8x +5.3%
Share count 21m 20m +3.1%

Biggest factor: revenue.

Last 3 years +62.6%

$1032.06 on November 3, 2023 to $1678.19

ThenNowEffect
Revenue (last 12 months) $4.0bn $4.1bn +4.5%
Net margin 20.5% 21.9% +6.8%
P/E multiple 28.4x 37.8x +32.9%
Share count 22m 20m +9.6%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
MTD+49%−15%−16%+1%+14%+20%
Industry peers (median)+4%−53%−3%−15%−7%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
MTD75%33%33%42%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
MTD−18%−36%−40%−24%−30%−32%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 44% from December 30, 2021 to October 30, 2023. Getting back needed a 77% gain, reached on October 29, 2026, 1095 days after the low.

Price behaviour

52-week range
$1025.53 – $1718.61
From 52-week high
−2.4%
vs 50-day average
+11.9%
vs 200-day average
+25.4%
Volatility (1 year)
31%
Beta vs S&P 500
0.80

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±5.2%
After a week
6 up, 6 down
typical move ±7.0%
After a month
7 up, 5 down
typical move ±6.8%
Results releasedNext dayS&P 500 next day5 days21 days
July 30, 2026 +2.0% +2.4% +2.4% +0.7%
May 7, 2026 −15.3% +0.5% −21.5% −14.2%
February 5, 2026 −1.2% +0.6% −2.3% −10.2%
November 6, 2025 0.0% −1.0% −1.9% −4.1%
August 1, 2025 −0.1% −0.1% +1.8% +3.4%
May 1, 2025 +2.7% +2.2% +2.9% +6.6%
November 7, 2024 −6.3% +1.2% −11.5% −8.3%
August 1, 2024 −5.2% −3.3% −8.3% −5.4%
May 9, 2024 +20.5% +0.7% +22.1% +15.2%
February 8, 2024 −3.2% +0.6% −1.7% +7.0%
January 10, 2024 +4.0% +0.5% +3.9% +3.0%
January 4, 2024 −1.3% −0.2% +3.4% +3.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Mettler Toledo’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Mettler Toledo in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Mettler Toledo
$3.7B $3.8B $3.9B $4B $4.1B $4.2B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $3.9B Revenue (TTM), FY23 Q4: $3.8B Revenue (TTM), FY24 Q1: $3.8B Revenue (TTM), FY24 Q2: $3.8B Revenue (TTM), FY24 Q3: $3.8B Revenue (TTM), FY24 Q4: $3.9B Revenue (TTM), FY25 Q1: $3.8B Revenue (TTM), FY25 Q2: $3.9B Revenue (TTM), FY25 Q3: $3.9B Revenue (TTM), FY25 Q4: $4B Revenue (TTM), FY26 Q1: $4.1B Revenue (TTM), FY26 Q2: $4.1B $4.1B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $3.9B
FY23 Q4 $3.8B
FY24 Q1 $3.8B
FY24 Q2 $3.8B
FY24 Q3 $3.8B
FY24 Q4 $3.9B
FY25 Q1 $3.8B
FY25 Q2 $3.9B
FY25 Q3 $3.9B
FY25 Q4 $4B
FY26 Q1 $4.1B
FY26 Q2 $4.1B
Revenue growth, TTM YoY Mettler Toledo
-10% -5% 0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 0.3% Revenue growth, TTM YoY, FY23 Q4: -3.4% Revenue growth, TTM YoY, FY24 Q1: -4.2% Revenue growth, TTM YoY, FY24 Q2: -5.2% Revenue growth, TTM YoY, FY24 Q3: -3.8% Revenue growth, TTM YoY, FY24 Q4: 2.2% Revenue growth, TTM YoY, FY25 Q1: 1.2% Revenue growth, TTM YoY, FY25 Q2: 3.1% Revenue growth, TTM YoY, FY25 Q3: 4.8% Revenue growth, TTM YoY, FY25 Q4: 4.0% Revenue growth, TTM YoY, FY26 Q1: 6.8% Revenue growth, TTM YoY, FY26 Q2: 6.9% 6.9%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 0.3%
FY23 Q4 -3.4%
FY24 Q1 -4.2%
FY24 Q2 -5.2%
FY24 Q3 -3.8%
FY24 Q4 2.2%
FY25 Q1 1.2%
FY25 Q2 3.1%
FY25 Q3 4.8%
FY25 Q4 4.0%
FY26 Q1 6.8%
FY26 Q2 6.9%
FCF margin (TTM) Mettler Toledo
18% 20% 22% 24% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 22.6% FCF margin (TTM), FY23 Q4: 22.7% FCF margin (TTM), FY24 Q1: 23.9% FCF margin (TTM), FY24 Q2: 24.0% FCF margin (TTM), FY24 Q3: 23.6% FCF margin (TTM), FY24 Q4: 22.3% FCF margin (TTM), FY25 Q1: 22.7% FCF margin (TTM), FY25 Q2: 21.9% FCF margin (TTM), FY25 Q3: 22.6% FCF margin (TTM), FY25 Q4: 21.1% FCF margin (TTM), FY26 Q1: 19.4% FCF margin (TTM), FY26 Q2: 20.9% 20.9%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 22.6%
FY23 Q4 22.7%
FY24 Q1 23.9%
FY24 Q2 24.0%
FY24 Q3 23.6%
FY24 Q4 22.3%
FY25 Q1 22.7%
FY25 Q2 21.9%
FY25 Q3 22.6%
FY25 Q4 21.1%
FY26 Q1 19.4%
FY26 Q2 20.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1,729 1,968 2,309 2,342 2,379 2,486 2,395 2,508 2,725 2,936 3,009 3,085 3,718 3,920 3,788 3,872 4,026 4,134
Gross profit 889 1,037 1,218 1,241 1,282 1,359 1,352 1,438 1,576 1,684 1,741 1,801 2,172 2,308 2,241 2,326 2,391 2,491
Net income 173 232 269 291 306 338 353 384 376 513 561 603 769 873 789 863 869 906
Diluted EPS $5.03 $6.80 $8.21 $9.14 $9.96 $11.44 $12.48 $14.22 $14.24 $19.88 $22.47 $24.91 $32.78 $38.41 $35.90 $40.48 $42.05 $44.44
Growth (year on year)
Revenue −12.4% +13.8% +17.3% +1.4% +1.6% +4.5% −3.6% +4.7% +8.6% +7.7% +2.5% +2.5% +20.5% +5.4% −3.4% +2.2% +4.0% +6.9%
Net income −14.9% +34.5% +16.1% +7.9% +5.2% +10.5% +4.3% +8.9% −2.2% +36.3% +9.5% +7.4% +27.6% +13.5% −9.6% +9.4% +0.7% +9.1%
Diluted EPS −13.1% +35.2% +20.7% +11.3% +9.0% +14.9% +9.1% +13.9% +0.1% +39.6% +13.0% +10.9% +31.6% +17.2% −6.5% +12.8% +3.9% +12.5%
Margins
Gross margin 51.4% 52.7% 52.8% 53.0% 53.9% 54.7% 56.4% 57.3% 57.8% 57.4% 57.9% 58.4% 58.4% 58.9% 59.2% 60.1% 59.4% 60.3%
Net margin 10.0% 11.8% 11.7% 12.4% 12.9% 13.6% 14.7% 15.3% 13.8% 17.5% 18.6% 19.5% 20.7% 22.3% 20.8% 22.3% 21.6% 21.9%
Free-cash-flow margin 10.0% 9.9% 7.9% 9.9% 11.1% 13.3% 14.9% 13.4% 14.3% 14.4% 16.8% 20.5% 21.6% 18.8% 22.7% 22.3% 21.1% 20.9%
Cash flow
Cash from operations 233 268 281 328 346 419 440 461 516 565 603 725 909 859 966 968 956 975
Capital spending 60 74 99 96 82 89 83 124 127 143 97 92 108 121 105 104 107 111
Free cash flow 173 194 182 232 264 330 357 337 389 422 506 632 801 738 861 864 849 864
Stock-based pay 11 12 12 13 13 14 14 15 17 18 18 19 20 20 18 20 23 23
Free cash flow after stock pay 161 182 170 219 251 316 343 321 372 405 488 614 782 718 843 844 826 841
Balance sheet
Cash 85 448 236 102 112 85 99 159 149 178 208 94 99 96 70 59 67 51
Total debt 204 681 505 389 413 452 590 894 980 1,035 1,291 1,334 1,682 2,015 2,081 2,014 2,152 2,112
Net debt (negative = net cash) 119 234 269 287 301 367 491 735 831 857 1,083 1,240 1,583 1,919 2,011 1,955 2,085 2,061
Diluted shares 34m 34m 33m 32m 31m 30m 28m 27m 26m 26m 25m 24m 23m 23m 22m 21m 21m 20m
Returned to shareholders
Buybacks 6 240 205 279 295 414 495 500 400 475 775 775 1,000 1,100 900 850 800 775
Total returned 6 240 205 279 295 414 495 500 400 475 775 775 1,000 1,100 900 850 800 775

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 6 checks passed · June 30, 2026
What it owns · $3.7bn
Short-term assets $1.3bnLonger-term assets $2.3bn
What it owes, and who funded it · $3.7bn
Short-term liabilities $1.2bnLonger-term liabilities $2.5bnShareholders' equity $13m
  • Short-term assets cover short-term liabilities $1.3bn of assets due within a year against $1.2bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.3bn short-term assets against $2.5bn of longer-dated liabilities.
  • More cash than debt $51m of cash against $2.1bn of debt.
  • Debt below 40% of shareholders' equity Debt is 16470% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 922% to 16470% over five years.
  • A year's operating cash flow covers at least 20% of debt $975m of operating cash flow against $2.1bn of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Mettler Toledo's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$775M
Returned to shareholders
90%
of free cash flow
Buybacks, last 3 fiscal years
$2.5B
Diluted share count
−3.0%
year over year
Total shareholder yield
2.1%
dividends 0.0% + buybacks 2.1% of market value
R&D spending
5.0%
of revenue
Sales & admin spending
24.9%
of revenue
Days sales outstanding
65 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated MTD CRL ILMN WAT BRKR MEDP Median
Revenue, last 12 months $4.1bn $4.0bn $4.5bn $4.6bn $3.5bn $2.8bn $229m
Revenue growth, last 12 months 6.9% −0.7% 5.8% 52.5% 1.6% 20.4% 6.9%
Revenue growth, 3-year average 1.5% −1.5% 0.5% 15.8% 8.8% 16.8% 2.9%
Revenue growth, latest quarter 4.5% −2.7% 4.2% 113.3% 5.2% 8.5% 8.5%
Gross margin 60.3% 36.7% 67.9% 59.3% 46.4% — 51.9%
Operating margin — 2.3% 21.2% 7.1% −0.9% 21.4% −14.3%
Operating margin, 3-year average — 6.4% 4.2% 20.5% 5.1% 20.9% −22.4%
Net margin 21.9% −6.0% 19.7% 3.6% −2.0% 18.2% −16.1%
Cash from operations / revenue 23.6% 14.6% 27.1% 11.8% 5.4% 25.5% 1.3%
Free-cash-flow margin 20.9% 9.3% 23.3% 9.4% 2.7% 23.5% −2.2%
Free-cash-flow margin, 3-year average 22.3% 11.9% 19.7% 17.5% 3.2% 26.0% 0.6%
Stock pay / revenue 0.6% 2.1% 5.9% 1.6% 0.6% 0.8% 4.4%
Change in share count −3.0% −3.9% −2.1% 25.7% −2.0% −5.1% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 6.9% 6.9% 27 of 54
Change in growth rate Growth +0.1pp +0.4pp 30 of 54
Gross margin Profitability 60.3% 52.0% 12 of 45
Net margin Profitability 21.9% -12.2% 1 of 54
Free-cash-flow margin Cash generation 20.9% -1.3% 8 of 54
Stock pay as % of revenue Cash generation 0.6% 4.4% 1 of 53
Long-term debt as % of assets Balance sheet 55.7% 26.3% 33 of 35
Change in share count Balance sheet -3.0% 1.0% 6 of 46
Days sales outstanding Balance sheet 65 days 62 days 28 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
US Operations $1.5B 37.2% ▲ 4.7%
Western European Operations $896M 22.3% ▲ 4.4%
Other Operations $789M 19.6% ▲ 6.9%
Chinese Operations $635M 15.8% ▲ 1.0%
Swiss Operations $211M 5.2% ▼ 3.5%
Products and services
Line of business Revenue YoY
Products $3B ▲ 2.6%
Laboratoryproductsandservices $2.2B ▲ 2.5%
Industrialproductsandservices $1.6B ▲ 6.0%
Services $1B ▲ 8.1%
Retailproductsandservices $206M ▲ 4.9%

These categories overlap or exclude eliminations, so shares aren't shown.

From Mettler Toledo's 10-K filed February 6, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$26.2B
Institutions reporting
802
Shares held vs prior quarter
▲ 3.2%
Positions opened / closed
71 / 89

Top buyers and sellers, Q2 2026: 319 institutions bought and 417 sold ; the biggest buyer was Capital International Investors (+441K shares) and the biggest seller Fundsmith LLP (−569K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $2.4B 1.9M 9.2% ▲ 6.3%
Capital International Investors $1.9B 1.5M 7.4% ▲ 40.8%
Vanguard Capital Management LLC $1.7B 1.3M 6.4% ▼ 0.2%
Vanguard Portfolio Management LLC $1.3B 1.0M 4.9% ▲ 1.4%
State Street Corp $1.2B 952K 4.6% ▲ 1.0%
T. Rowe Price Investment Management, Inc. $887M 694K 3.4% ▼ 5.1%
Alliancebernstein L.P. $856M 679K 3.3% ▼ 10.3%
Geode Capital Management, LLC $780M 612K 3.0% ▲ 1.1%
Bank Of New York Mellon Corp $763M 597K 2.9% ▼ 15.1%
Morgan Stanley $594M 465K 2.3% ▼ 4.7%
Wellington Management Group LLP $586M 459K 2.2% ▲ 908.6%
Norges Bank $510M 400K 1.9% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Mettler Toledo's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $35.9M 19 trades by 6 insiders · 0% under pre-set plans
Net ▼ $35.9M net selling
Insider Date Trade Shares Price Value
Kaltenbach Patrick President and CEO August 27, 2026 Sell 942 $1425.00 $1.3M
Salice Thomas P Director August 5, 2026 Sell 417 $1440.41 $600,651
Vadala Shawn Chief Financial Officer August 3, 2026 Sell 2,240 $1432.00 $3.2M
Keller Gerry Head of Process Analytics August 3, 2026 Sell 240 $1427.14 $342,514
Salice Thomas P Director August 3, 2026 Sell 415 $1444.62 $599,517
Vadala Shawn Chief Financial Officer February 10, 2026 Sell 800 $1410.12 $1.1M
Vadala Shawn Chief Financial Officer November 25, 2025 Sell 1,000 $1511.00 $1.5M
De La Guerroniere Marc Head of Eur & NA Market Orgs November 25, 2025 Sell 2,475 $1500.00 $3.7M
De La Guerroniere Marc Head of Eur & NA Market Orgs November 25, 2025 Sell 3,580 $1480.00 $5.3M
Vadala Shawn Chief Financial Officer November 24, 2025 Sell 1,025 $1452.00 $1.5M
Keller Gerry Head of Process Analytics November 21, 2025 Sell 236 $1418.58 $334,785
Kaltenbach Patrick President and CEO November 12, 2025 Sell 925 $1463.88 $1.4M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 10 trades and filings

In the last 12 months, 1 member of Congress disclosed 0 purchases and 1 sale of Mettler Toledo shares.

  • Julia Letlow(R-LA 5):Sale (full), $1,001 - $15,000, traded December 8, 2025, filed January 13, 2026
  • Julia Letlow(R-LA 5):Purchase, $1,001 - $15,000, traded July 25, 2025, filed January 13, 2026
  • Robert P. Bresnahan, Jr.(R-PA 8):Purchase, $1,001 - $15,000, traded May 15, 2025, filed May 31, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 30, 2026 estimated from the company's past filing pattern, not announced

  • July 30, 2026
  • May 7, 2026
  • February 5, 2026
  • November 6, 2025
  • August 1, 2025
  • May 1, 2025

Recent SEC filings

Data status

When each part of this page on Mettler Toledo was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Mettler Toledo in brief

What does Mettler Toledo do?
Mettler Toledo is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Mettler Toledo's stock ticker?
Mettler Toledo trades under the ticker MTD on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Mettler Toledo's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Mettler Toledo reported revenue of $4.1B, 6.9% higher than a year earlier, according to its SEC filings.
What is Mettler Toledo's free cash flow?
Mettler Toledo's free-cash-flow margin is 20.9% of revenue over the trailing twelve months, ranking 8 of the 54 life sciences tools & services companies we cover.
What is Mettler Toledo's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Mettler Toledo's free cash flow after stock-based pay gives ~$740 per share in the base case, and ~$530–$1000 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Mettler Toledo's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Capital International Investors and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Mettler Toledo buying back stock, and does it pay a dividend?
Mettler Toledo spent $775M on share repurchases over the trailing twelve months, and its diluted share count fell 3.0% over the year.
What is Mettler Toledo's market cap?
On November 2, 2026, Mettler Toledo's market capitalisation was about $34.2B, with a price-to-earnings ratio of 37.8 and net debt of $2.1B. Market figures come from third-party market data and may be delayed.
How much debt does Mettler Toledo have?
Mettler Toledo's debt-to-equity ratio is 16470.1%, from its latest balance sheet (922.2% five years earlier). The financial health section below sets out its other solvency checks.
Who are Mettler Toledo's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Mettler Toledo are Charles River Laboratories, Illumina, Inc., Waters Corporation, Bruker Corp and Medpace Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Mettler Toledo's.
Are insiders buying or selling Mettler Toledo stock?
Over the last 12 months, Mettler Toledo's directors and officers reported 0 open-market purchases and 19 sales on Form 4. The insider trading page charts every trade.
When is Mettler Toledo's next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Mettler Toledo announces its own schedule.